Our Take
Congressional pressure on Medicare AI pilots is now explicit—lawmakers are not waiting for a scandal to demand numbers on care delays, and CMS has no cover to keep data private.
Why it matters
Prior authorization AI systems directly affect patient access to care. If an AI tool is slowing approvals without proven benefit, it becomes a political liability for CMS and a data-transparency test case for healthcare regulators.
Do this week
Health system compliance leads: audit your prior authorization workflows now to map which decisions are AI-assisted, document approval time deltas, and prepare for incoming congressional or state-level data requests.
Democrats press CMS for WISeR transparency
A group of Democratic lawmakers has sent a letter to the Centers for Medicare and Medicaid Services demanding detailed data on WISeR, an AI-powered prior authorization system used in the Medicare program. The letter, reported by Healthcare Dive, reflects growing concern that the tool is delaying care decisions for beneficiaries without justification.
WISeR uses artificial intelligence to streamline the prior authorization process, which typically requires doctors to get approval before certain treatments or procedures are covered. The system was designed to reduce administrative burden, but critics argue it may instead be creating new bottlenecks by slowing the approval timeline for time-sensitive care.
This is not the first legislative challenge to the pilot. Congressional scrutiny of WISeR has intensified as anecdotal reports of delayed approvals have circulated, and lawmakers are now formally requesting performance metrics and approval timelines from CMS.
Prior authorization AI is now a legislative priority
Prior authorization is a known friction point in healthcare delivery. Administrative delays in approval processes can deny patients timely access to necessary care. When an AI system becomes part of that bottleneck, it raises two overlapping concerns: whether the system is working as intended, and whether CMS has adequate oversight.
The letter signals that Congress is not content with vendor claims or internal CMS assessments alone. Lawmakers are demanding independent data, which sets a precedent for how other healthcare AI pilots will be evaluated under public scrutiny. This also raises the political temperature around any AI deployment that touches patient care timelines.
For healthcare organizations and payers, the move is a clear signal that AI prior authorization tools will face regulatory and legislative pressure if approval times increase or patient outcomes appear to suffer. Transparency and benchmarking against non-AI baselines are no longer optional.
Prepare documentation now, not later
Health system compliance and operations teams should immediately audit their own AI-assisted prior authorization workflows. Document the average approval time before and after any AI intervention, capture rejection and appeal rates, and flag cases where AI decisions were overridden by human reviewers. This data will become table stakes in any congressional inquiry, state-level audit, or vendor dispute.
If your organization uses WISeR or similar systems, begin gathering comparative metrics now. Do not wait for a formal request. The political momentum is building, and evidence of diligent internal oversight will shield your organization from being caught flat-footed when regulators or legislators come calling.